# Adversarial verification verdict - papillary_renal_cell_carcinoma

## 1. DOSE LEAK
None. Grepped the sidecar for mg / mg-m2 / AUC / numbered cycle-day schedules -
no matches. The only numbers present are efficacy statistics (foretinib ORR
~13.5%, PFS ~9.3 months, both directly sourced from DeVita's foretinib trial
text) and a surveillance interval ("every three to six months" for active
surveillance imaging, also directly lifted from DeVita's AS section) - neither
is a drug dose or administration schedule.

## 2. UNGROUNDED CLAIMS
Spot-checked against DeVita Ch. 43 "Cancer of the Kidney" (pp. 734-747, source
lines ~149781-150910 of devita.txt) plus the mTOR-inhibitor pharmacology
chapter (source lines ~28028-28031).

- All biology claims (MET/type 1, CDKN2A/SETD2/TFE3-TFEB/NRF2/type 2, HLRCC-FH,
  CIMP subgroup with worst survival) - confirmed verbatim-level match to
  DeVita pp. 735-737.
- Localized disease (RN/PN/TA/AS options, PN as SOC, AS criteria <2cm/Bosniak
  3-4/surveillance interval/slow growth+low met potential over 2-3y) -
  confirmed match to DeVita pp. 738-742 (Table 43.5, AS section).
- Papillary histology as independent predictor of worse CSS in IVC
  thrombectomy series (alongside fat invasion, thrombus level) - confirmed,
  matches the 1,774-patient multi-institutional series in DeVita p.743
  (sidecar correctly omits the HR/CI numbers from that study).
- Lymphadenectomy as staging-not-therapeutic tool, selective use in younger/
  FH-papillary type 2/adjuvant-trial candidates, standard when nodes
  radiographically involved - confirmed near-verbatim match to DeVita p.743.
- ASSURE (sunitinib/sorafenib/placebo, no DFS benefit), S-TRAC (sunitinib vs
  placebo, modest DFS benefit/no OS benefit, high discontinuation both trials)
  - confirmed match to DeVita pp.744-745 and Table 43.7.
- "Other adjuvant trials (axitinib, pazopanib) largely negative/inconsistent"
  - confirmed: ATLAS (axitinib) negative; PROTECT (pazopanib) positive only in
  the 800mg-tolerant subgroup (26% of cohort) with added toxicity, negative in
  the 600mg group - "largely negative or inconsistent" is a fair compression.
- "Adjuvant checkpoint-inhibitor trials that enrolled all RCC histologies
  (including papillary) had not reported results" - VERIFIED AS ACCURATE AND
  PRECISE: Table 43.7 shows KEYNOTE-564, CHECKMATE 914, and IMotion010 all
  restricted to "RCC with clear cell or sarcomatoid component" (excludes pure
  papillary), while the two histology-inclusive trials, PROSPER and RAMPART,
  are listed as "Not reported" / "Recruiting" respectively. The sidecar
  correctly distinguishes histology-restricted (reported) vs. histology-
  inclusive (unreported) checkpoint trials rather than conflating them - a
  genuinely careful read of the source table, not a fabrication.
- Foretinib phase II trial (MET/VEGFR2 multikinase inhibitor, bilateral/
  multifocal/metastatic papillary RCC incl. germline MET-mutated HPRC, ORR
  13.5%, PFS 9.3 months, best response in germline MET-mutation carriers) -
  confirmed match to DeVita p.736. Minor note: DeVita's text describes
  foretinib only as "a multikinase inhibitor that targets MET among other
  tyrosine kinases" and does not spell out "VEGFR2" by name in this passage;
  the sidecar's "MET/VEGFR2" is standard, uncontroversial pharmacology for
  foretinib (also known as XL880) but is a small unflagged addition beyond
  the literal DeVita sentence - low-severity, not a clinical-management
  fabrication.
- Everolimus/mTOR-inhibitor histology-response claim ("efficacy maintained
  across histologic subtypes, more pronounced in chromophobe than other
  non-clear-cell types") - confirmed match to DeVita's mTOR-inhibitor
  pharmacology chapter (line ~28028: "Everolimus efficacy is maintained
  independent of the histology with seemingly stronger activity on chromophobe
  non-clear cell RCC than other non-clear cell histology types"). Correctly
  flagged inline as drawn from a different chapter, not the kidney-cancer
  section, exactly as disclosed by the draft agent.
- CDKN2A silencing frequency, IVC thrombectomy HRs, adjuvant trial HR/CI
  numbers, foretinib trial n, S-TRAC/ASSURE discontinuation percentages - all
  correctly omitted by the sidecar (present in DeVita but left out), which is
  appropriate restraint, not a gap.
- Metastatic RCC general drug-class sequencing (VEGF-TKI -> mTOR inhibitor ->
  checkpoint-inhibitor combos "sequenced by risk group and prior therapy") -
  explicitly and correctly flagged inline as general oncology practice, not
  DeVita's kidney chapter (DeVita's chapter indeed does not lay out a
  papillary-specific systemic algorithm beyond foretinib).
- Monitoring/imaging-interval statement - explicitly and correctly flagged as
  general practice, not DeVita-specific (DeVita's chapter has no fixed
  papillary surveillance schedule).

No specific regimen, drug, trial, or statistic was found that lacked support
in DeVita or an explicit "general oncology standard" flag.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles &
Practice of Oncology, 12th ed." - name only, no page numbers. Correct format.

## 4. VERDICT
CLEAN (ready for R1).

Only a trivial, low-severity note: the foretinib description "MET/VEGFR2
multikinase inhibitor" adds "VEGFR2" beyond DeVita's literal wording ("a
multikinase inhibitor that targets MET among other tyrosine kinases"). This
is standard, uncontroversial pharmacology for foretinib/XL880 and not a
clinical-management fabrication or dose leak - flagging for R1's awareness
only, not a blocking issue.
